Repligen (NASDAQ:RGEN) Shares Down 2.2% – Should You Sell?

Repligen Co. (NASDAQ:RGEN) fell 2.2% on Wednesday . The company traded as low as $141.13 and last traded at $141.82. 19,791 shares traded hands during mid-day trading, a decline of 97% from the average session volume of 661,426 shares. The stock had previously closed at $144.98.

Analyst Ratings Changes

A number of brokerages have weighed in on RGEN. UBS Group decreased their target price on shares of Repligen from $205.00 to $185.00 and set a “buy” rating for the company in a research note on Wednesday, July 31st. Wells Fargo & Company assumed coverage on shares of Repligen in a report on Tuesday, August 27th. They issued an “overweight” rating and a $180.00 target price for the company. Benchmark reissued a “hold” rating on shares of Repligen in a report on Monday, August 5th. Guggenheim assumed coverage on shares of Repligen in a research report on Tuesday, June 18th. They set a “neutral” rating on the stock. Finally, Stephens reissued an “overweight” rating and issued a $170.00 price objective on shares of Repligen in a research report on Tuesday, July 30th. Two research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $190.25.

Repligen Price Performance

The company has a market capitalization of $7.72 billion, a PE ratio of 579.92, a P/E/G ratio of 4.05 and a beta of 0.95. The company’s 50-day simple moving average is $146.74 and its 200-day simple moving average is $148.86. The company has a debt-to-equity ratio of 0.26, a quick ratio of 5.56 and a current ratio of 6.65.

Repligen (NASDAQ:RGEN) last announced its earnings results on Tuesday, July 30th. The biotechnology company reported $0.33 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.33. The company had revenue of $154.07 million during the quarter, compared to analysts’ expectations of $154.11 million. Repligen had a negative net margin of 0.32% and a positive return on equity of 3.36%. The firm’s quarterly revenue was down 3.2% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.53 earnings per share. As a group, sell-side analysts anticipate that Repligen Co. will post 1.45 earnings per share for the current year.

Insider Activity at Repligen

In other Repligen news, Director Anthony Hunt sold 22,191 shares of the business’s stock in a transaction that occurred on Tuesday, September 10th. The shares were sold at an average price of $145.37, for a total transaction of $3,225,905.67. Following the completion of the sale, the director now directly owns 139,840 shares in the company, valued at $20,328,540.80. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In related news, VP Ralf Kuriyel sold 4,465 shares of the company’s stock in a transaction on Thursday, August 1st. The shares were sold at an average price of $165.67, for a total value of $739,716.55. Following the sale, the vice president now directly owns 19,261 shares of the company’s stock, valued at $3,190,969.87. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Anthony Hunt sold 22,191 shares of the company’s stock in a transaction on Tuesday, September 10th. The shares were sold at an average price of $145.37, for a total transaction of $3,225,905.67. Following the completion of the sale, the director now directly owns 139,840 shares in the company, valued at $20,328,540.80. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 1.20% of the stock is owned by insiders.

Institutional Trading of Repligen

Several institutional investors have recently added to or reduced their stakes in RGEN. Vanguard Group Inc. raised its holdings in shares of Repligen by 0.4% during the first quarter. Vanguard Group Inc. now owns 5,100,013 shares of the biotechnology company’s stock worth $937,994,000 after purchasing an additional 21,719 shares during the period. Bank of New York Mellon Corp raised its holdings in shares of Repligen by 21.0% during the second quarter. Bank of New York Mellon Corp now owns 1,370,375 shares of the biotechnology company’s stock worth $172,749,000 after purchasing an additional 237,884 shares during the period. Conestoga Capital Advisors LLC raised its holdings in shares of Repligen by 26.7% during the second quarter. Conestoga Capital Advisors LLC now owns 946,877 shares of the biotechnology company’s stock worth $119,363,000 after purchasing an additional 199,322 shares during the period. Thrivent Financial for Lutherans raised its holdings in shares of Repligen by 240.5% during the second quarter. Thrivent Financial for Lutherans now owns 601,829 shares of the biotechnology company’s stock worth $75,866,000 after purchasing an additional 425,061 shares during the period. Finally, Dimensional Fund Advisors LP raised its holdings in shares of Repligen by 39.4% during the second quarter. Dimensional Fund Advisors LP now owns 429,524 shares of the biotechnology company’s stock worth $54,149,000 after purchasing an additional 121,305 shares during the period. 97.64% of the stock is owned by institutional investors and hedge funds.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.